biostudies-literatureTalebian HNew Frontiers in Research Fund - Transformation11651https://www.ebi.ac.uk/biostudies/studies/S-EPMC12692291biostudies-literatureUnknown26(23)Prostate cancer (PCa), particularly in its metastatic form, remains a major clinical challenge due to limited diagnostic and therapeutic options. To address this, we developed a novel radiotheranostic agent, [<sup>64</sup>Cu]Cu-NOTA-TP-PSMA, by conjugating a prostate-specific membrane antigen (PSMA) ligand to a <sup>64</sup>Cu-radiolabeled terpyridine-platinum (TP) compound previously shown to exert selective cytotoxicity against cancer cells. In this study, the biological performance of [<sup>64</sup>Cu]Cu-NOTA-TP-PSMA was compared with the monomeric analogs [<sup>64</sup>Cu]Cu-NOTA-PSMA and [<sup>64</sup>Cu]Cu-NOTA-TP through in vitro studies in PSMA-positive LNCaP prostate cancer cells and non-malignant HEK-293 cells. [<sup>64</sup>Cu]Cu-NOTA-TP-PSMA showed high stability, PSMA binding International journal of molecular sciencesDevelopment and In Vitro Evaluation of [<sup>64</sup>Cu]Cu-NOTA-TP-PSMA, a Novel Radiotheranostic Agent Against Prostate Cancer.PMC12692291NFRFT-2022-00269Ignatius Arokia Doss PMAit-Mohand STalebian HSanche LGuerin BfalseDevelopment and In Vitro Evaluation of [<sup>64</sup>Cu]Cu-NOTA-TP-PSMA, a Novel Radiotheranostic Agent Against Prostate Cancer.Prostate cancer (PCa), particularly in its metastatic form, remains a major clinical challenge due to limited diagnostic and therapeutic options. To address this, we developed a novel radiotheranostic agent, [<sup>64</sup>Cu]Cu-NOTA-TP-PSMA, by conjugating a prostate-specific membrane antigen (PSMA) ligand to a <sup>64</sup>Cu-radiolabeled terpyridine-platinum (TP) compound previously shown to exert selective cytotoxicity against cancer cells. In this study, the biological performance of [<sup>64</sup>Cu]Cu-NOTA-TP-PSMA was compared with the monomeric analogs [<sup>64</sup>Cu]Cu-NOTA-PSMA and [<sup>64</sup>Cu]Cu-NOTA-TP through in vitro studies in PSMA-positive LNCaP prostate cancer cells and non-malignant HEK-293 cells. [<sup>64</sup>Cu]Cu-NOTA-TP-PSMA showed high stability, PSMA binding 2025-01-01T00:00:00Z2025 Dec2026-05-26T11:01:42.72Z2026-05-24T03:11:15.956ZS-EPMC126922914137380310.3390/ijms262311651